Mar. 10 at 3:11 PM
The B2i Digital team is pleased to announce that MetaVia Inc. (Nasdaq:
$MTVA) is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Thursday, March 12, 2026, at 10:30 AM EDT. The session will be moderated by David Bautz, PhD, Senior Analyst at Zacks Small Cap Research.
The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum
Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets.
MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is developing DA-1726 for the treatment of obesity and vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin analogue functioning as a dual GLP-1 receptor and glucagon receptor agonist, which in a Phase 1 multiple ascending dose trial demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction. Vanoglipel is a novel GPR119 agonist that promotes the release of key gut peptides and, in a Phase 2a clinical study, demonstrated direct hepatic action in addition to glucose-lowering effects.
Presenting on behalf of MetaVia will be HH Kim, Chief Executive Officer and President. Prior to his current role, Mr. Kim served as General Counsel and Senior Vice President of Dong-A ST and Dong-A Socio Group, where he negotiated numerous licensing and investment transactions. He holds a Bachelor of Law degree from Soongshil University and a Juris Doctor from Washington University School of Law.
To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5259493/metavia-inc-nasdaq-mtva?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC
For more information about MetaVia, visit: https://ir.metaviatx.com
Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.
